LONGEVERON INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.3 USD | -10.65% |
|
-22.62% | -90.44% |
| May. 10 | Longeveron Inc. Announces Board Changes | CI |
| Apr. 30 | Longeveron Files Prospectus for Secondary Offering | MT |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to Longeveron's call...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Longeveron Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The Company is primarily focused on three pipeline indications, which include Hypoplastic Left Heart Syndrome (HLHS), Alzheimerâs disease (AD) and Aging-related Frailty. Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The Company has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.
Calendar
2024-05-13
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.3
USD
Average target price
14.05
USD
Spread / Average Target
+980.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -90.44% | 9.36M | |
| +26.37% | 48.16B | |
| -1.01% | 41.73B | |
| +42.38% | 41.03B | |
| -5.31% | 28.77B | |
| +9.34% | 25.59B | |
| -21.69% | 18.96B | |
| +6.23% | 12.92B | |
| +26.99% | 12.03B | |
| -3.38% | 11.77B |
- Stock Market
- Equities
- LGVN Stock
- News Longeveron Inc.
- Transcript : Longeveron Inc., Q1 2023 Earnings Call, May 12, 2023